Home › Grants › United States › Translational Efforts to Advance Gene-based Therapies for Ultra-Rare N

Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)

The Ultra-Rare Gene-Based Therapy (URGenT) network supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human (FIH) clinical testing of gene-based or transcript-directed therapeutics, such as oligonucleotides and viral-based gene therapies, for ultra-rare...

Grant (non-repayable) Open now

Funder

National Institutes of Health
Funder profile and all of its programs

Amount

Award amounts are not published in the listing; see the official page.

Where

United States (federal)

Eligibility

Open to businesses, self-employed people, nonprofits, colleges, universities, schools or research institutions and state, provincial, local or tribal governments. No cost sharing is required.

Sectors

Health and life sciences, Nonprofits and charities, Research and science

Deadline

Closes 8 October 2027

Source

Grants.gov XML extract (PAR-25-327)

Last checked

2 November 2026

Funder contacts

Public organizational contacts on file Unlock full profile / Sign up

Official page ↗

From official open data: listed in the official Grants.gov extract on 2026-11-02. The summary is from the official listing; the eligibility line is our plain-language reading of its eligibility codes. Confirm details on the official page.

Related grant lists

Health and life sciences Nonprofits and charities Research and science Governments and public bodies Schools, colleges and research institutions Nonprofits and charities United States United States (national) Federal agency October 2027

Information only. GrantSift is not affiliated with any funder. A match means a program is likely eligible or worth checking, not that you will be funded. Always confirm details on the official page. Applying through official portals is free.